Passage Bio, Inc. Form 8-K Summary
Business Context and Reporting Date
Passage Bio, Inc. filed this Current Report on Form 8-K on March 27, 2020, reporting an event occurring on March 26, 2020. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol PASG.
Material Corporate Action
On March 26, 2020, the company’s Board of Directors adopted amended and restated bylaws. The amendments designate the federal district courts of the United States as the exclusive forum for litigation arising under the Securities Act of 1933, as amended.
The filing states that the summary is qualified in its entirety by reference to the full amended and restated bylaws, filed as Exhibit 3.1.
Financial Metrics and Liquidity
This filing does not provide revenue, profitability, cash flow, margins, debt, liquidity, guidance, or other financial metrics.
Risks, Contingencies, and Unusual Items
The exclusive-forum provision may affect where Securities Act claims against the company or its directors and officers can be brought. The filing does not describe any specific litigation, contingency, or financial impact resulting from the amendment.
Important Facts to Verify
- Review Exhibit 3.1 for the complete language and scope of the amended and restated bylaws.
- Confirm the applicability and enforceability of the federal exclusive-forum provision under the Securities Act.
- Refer to the company’s periodic reports for financial results, liquidity, operating risks, and forward-looking guidance, which are not included in this 8-K.